Unbiased and Practical Psychopharmacology Updates

Get exclusive psychopharmacology updates. Earn up to 155 CMEs, including 40 SA CMEs credits.

Explore Memberships

Receive psychopharmacology updates in your inbox

TRENDING IN PSYCHOPHARMACOLOGY INSTITUTE

Quick Takes

Five research summaries in adult psychiatry, each month. CME available for Silver and Gold members.

“Cade’s Disease” and Beyond: Misdiagnosis, Antidepressant Use, and a Proposed Definition for Bipolar Spectrum Disorder

Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis

Effect of Anxiolytic Drug Silexan on Sleep – A Narrative Review

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

Intermittent Selective Serotonin Reuptake Inhibitors for Premenstrual Syndromes: A Systematic Review and Meta-Analysis of Randomized Trials

View All

Expert Consultations

We interview experts who share clinical pearls for your busy practice. CME available for Silver and Gold members.

Pharmacotherapies for Stimulant Use Disorder – Interview

Pharmacologic Management of BPD: Recent Developments-Interview

Antipsychotic Switching: Intersection of Art and Science – Interview

Management of Behavioral and Psychological Symptoms of Dementia – Interview

OCD in Children and Adolescents – Interview

View All

Video Lectures

A selection of practical sections from our video lectures. CME available for Bronze, Silver, and Gold members.

Initiating and Optimizing Clozapine

Treating Anxiety Disorders in Patients With Cancer

Prevalence, Assessment, and Management of RBD

Considerations for Using Benzodiazepines and Benzodiazepine Receptor Agonists in the Geriatric Population

Use of Omega-3 Fatty Acids in Children and Adolescents

View All

RECENT PUBLICATIONS

Quick Take Vol. 85

0.50 CMEs
Does Cobenfy maintain its efficacy and safety after one year of use? Should we reconsider trazodone for depression-associated insomnia despite AASM guidelines? Is antidepressant monotherapy in bipolar I as risky as previously thought? Does inflammation explain treatment resistance in older depressed adults? What risk factors predict stimulant misuse and diversion in ADHD patients?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., James Phelps, M.D., Paul Zarkowski, M.D.
33.5 minutes in 5 audio sections

Q1 2026 in Review: Milsaperidone, GLP-1 RAs, and Zuranolone

0.50 CMEs
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA’s removal of the GLP-1 suicidality warning mean for your practice? How does ACOG’s updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Use of Long-Acting Injectable Antipsychotics in Schizophrenia – Interview

0.50 CMEs
A discussion on long-acting injectable antipsychotics in schizophrenia, covering collaborative decision making, patient engagement strategies, LAI selection, dosing and switching considerations, injection site management, use in pregnancy, and emerging pipeline agents for expanding treatment options.
Brian Miller, M.D., Ph.D., M.P.H.
Augusta University
34.06 minutes of audio interview

Addiction Psychopharmacology in Patients with Medical Comorbidities

1.25 CMEs
A practical guide to adjusting addiction pharmacotherapy in patients with significant medical comorbidities. Dr. Sevarino provides evidence-based dosing modifications for naltrexone, buprenorphine, methadone, and disulfiram across liver disease, renal impairment, cardiovascular disease, respiratory conditions, and infectious comorbidities, with integrated care frameworks for complex cases.
Kevin A. Sevarino, M.D.C.M., Ph.D.
Yale School of Medicine
72.5 minutes in 10 sections

Gastrointestinal Side Effects of Antidepressants: Mechanisms, Comparison and Management Strategies

0.50 CMEs
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Quick Take Vol. 84

0.75 CMEs
When should you taper a benzodiazepine, and how slowly? Does semaglutide reverse metabolic risk in schizophrenia patients on clozapine or olanzapine? Is EPA effective for TRD? Can brief psychotherapy enable safe antidepressant discontinuation? Is a ketogenic diet effective for depression and other psychiatric conditions?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D., Paul Zarkowski, M.D., James Phelps, M.D.
47.02 minutes in 5 audio sections

Explore our library of over 480 video lectures, podcasts, research summaries, and expert interviews.

Explore Our Library

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

Lost as a newly-matched psychiatry resident?

Access ALL our products FREE for 3 months!

Get Instant Access